BioNexus Gene Lab (BGLC) Short Interest Ratio & Short Volume

Short interest is the volume of BioNexus Gene Lab shares that have been sold short but have not yet been closed out or covered. As of May 31st, investors have sold 61,700 shares of BGLC short. 5.27% of BioNexus Gene Lab's shares are currently sold short. Learn More on BioNexus Gene Lab's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.27% of BioNexus Gene Lab's floating shares are currently sold short.

BioNexus Gene Lab saw a decrease in short interest in May. As of May 31st, there was short interest totaling 61,700 shares, a decrease of 3.0% from the previous total of 63,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

BioNexus Gene Lab currently has issued a total of 1,797,000 shares. Some of BioNexus Gene Lab's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. BioNexus Gene Lab currently has a public float of 1,170,000 shares.

5.27% of BioNexus Gene Lab's shares are currently sold short. Here is how the short interest of companies in the industry of "healthcare" compare to BioNexus Gene Lab: Enzo Biochem, Inc. (0.97%), BioRestorative Therapies, Inc. (2.61%), Mangoceuticals, Inc. (4.65%), SunLink Health Systems, Inc. (0.97%), Ontrak, Inc. (0.76%), ATI Physical Therapy, Inc. (0.30%), Vsee Health, Inc. (0.46%), Aclarion, Inc. (2.46%), NewGenIvf Group Limited (36.51%), IMAC Holdings, Inc. (2.16%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks.

Short selling BGLC is an investing strategy that aims to generate trading profit from BioNexus Gene Lab as its price is falling. BGLC shares are trading down $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for BioNexus Gene Lab occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BGLC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BGLC, twice per month. The most recent reporting period available is May, 31 2025.